{"entity":{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","aka":[],"tldr":"Breast cancer physician scientist who has directed the Holden Comprehensive Cancer Center at the University of Iowa since October 2024.","summary":"Mark E. Burkard, MD, PhD, became Director of the Holden Comprehensive Cancer Center on 1 October 2024. He holds the C.E. Block Chair of Cancer Research and is Professor and Associate Dean for Cancer in the University of Iowa Carver College of Medicine. His research focuses on understanding the drivers of genomic changes in breast cancer and developing precision treatments. The centre's leadership page lists Jon C. Houtman as Deputy Director of Research.","asOf":"2026-09-10","links":[{"label":"Source: Holden Comprehensive Cancer Center leadership page","url":"https://holden.uihealthcare.org/about/leadership"}],"tags":["leadership","clinician-scientist","comprehensive-cancer-centre"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iowa-holden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Holden Comprehensive Cancer Center, University of Iowa","institutionId":"iowa-holden","specialisms":["Breast cancer","Cancer genomics","Precision oncology"],"profiles":[{"label":"Holden leadership page","url":"https://holden.uihealthcare.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Burkard+ME%5BAuthor%5D"}],"papers":[{"title":"Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer","journal":"BMC Cancer","year":2016,"doi":"10.1186/s12885-016-2083-x"},{"title":"Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer","journal":"Molecular Cancer Therapeutics","year":2021,"doi":"10.1158/1535-7163.mct-21-0195"},{"title":"E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.21.00944"}],"orcid":"0000-0002-4215-7722"},"route":"/people/mark-burkard/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"institution":[{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/"}]}}